1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Endometrial Adenocarcinoma: new trials by email Literature Review of Recurrent Endometrial Adenocarcinoma trials Research Report on Recurrent Endometrial Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Carboplatin, Computed Tomography, Paclitaxel - Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 813 | 2019-08-22 | 2026-10-21 |
Carcinosarcoma (1) · Endometrial Neoplasms (1)
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Complex and Mixed (1) · Neoplasms, Connective and Soft Tissue (1) · Sarcoma (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
Carboplatin (1) · Paclitaxel (1) · Taxes (1) · pembrolizumab (1)
National Cancer Institute (NCI) (1)
Canada (1) · Japan (1) · Puerto Rico (1) · South Korea (1) · United States (1)
Ramez N Eskander (1)
PMID 36972022, PMID 37411031, PMID 38431043, PMID 40044930
U10CA180868 (1)